{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:43:09Z","timestamp":1775263389684,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clml.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T23:21:36Z","timestamp":1620688896000},"page":"676-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["FLT3-ITD Allele Frequency Is an Independent Prognostic Factor for Poor Outcome in FLT3-ITD\u2013Positive AML Patients"],"prefix":"10.1016","volume":"21","author":[{"given":"Nevine F.","family":"Shafik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira D.","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha Mahmoud","family":"Allam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada M.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.05.005_bib0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0609.2012.01785.x","article-title":"Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia","volume":"89","author":"Schiller","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.05.005_bib0002","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?","volume":"6","author":"Levis","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.05.005_bib0003","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/bloodadvances.2018020305","article-title":"Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia","volume":"2","author":"Sakaguchi","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.05.005_bib0004","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404368","article-title":"The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients","volume":"20","author":"Ponziani","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.005_bib0005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11899-014-0203-8","article-title":"FLT3 inhibitors in AML: are we there yet?","volume":"9","author":"Sudhindra","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2021.05.005_bib0006","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2021.05.005_bib0007","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0008","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0009","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/leu.2011.97","article-title":"Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia","volume":"25","author":"Schnittger","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.005_bib0010","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2005-08-3453","article-title":"Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia","volume":"107","author":"Stirewalt","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0011","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3109\/10428194.2013.850163","article-title":"Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort","volume":"55","author":"Koszarska","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.05.005_bib0012","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.05.005_bib0013","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ajh.25553","article-title":"Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with\/without sorafenib","volume":"94","author":"Yalniz","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.05.005_bib0014","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4274\/tjh.2017.0095","article-title":"NPM1 mutation analysis in acute myeloid leukemia: comparison of three techniques - Sanger sequencing, pyrosequencing, and real-time polymerase chain reaction","volume":"35","author":"Kumar","year":"2018","journal-title":"Turk J Hematol"},{"key":"10.1016\/j.clml.2021.05.005_bib0015","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0016","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1080\/10428194.2017.1399312","article-title":"The importance of FLT3 mutational analysis in acute myeloid leukemia","volume":"59","author":"Patnaik","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.05.005_bib0017","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.7314\/APJCP.2015.16.12.4869","article-title":"Characterisation and clinical significance of FLT3-ITD and non-ITD in acute myeloid leukaemia patients in Kelantan, Northeast Peninsular Malaysia","volume":"16","author":"Yunus","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clml.2021.05.005_bib0018","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","article-title":"The structural basis for autoinhibition of FLT3 by the juxtamembrane domain","volume":"13","author":"Griffith","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.clml.2021.05.005_bib0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood-2014-02-554667","article-title":"Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia","volume":"124","author":"Linch","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0021","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0022","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41409-019-0721-z","article-title":"Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation","volume":"55","author":"Chen","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.05.005_bib0023","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood.2019002697","article-title":"Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia","volume":"135","author":"D\u00f6hner","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0024","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.2147\/CMAR.S225123","article-title":"Impact of ELN risk stratification, induction chemotherapy regimens and hematopoietic stem cell transplantation on outcomes in hyperleukocytic acute myeloid leukemia with initial white blood cell count more than 100\u00a0\u00d7\u00a0109\/L","volume":"11","author":"Feng","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2021.05.005_bib0025","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","article-title":"FLT3\/ITD AML and the law of unintended consequences","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0026","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0027","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.2147\/CMAR.S194523","article-title":"Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis","volume":"11","author":"Huang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2021.05.005_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719899818","article-title":"Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2021.05.005_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0268-7","article-title":"Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia","volume":"10","author":"Xu","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.05.005_bib0030","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2016.65","article-title":"Genetic alterations and their clinical implications in older patients with acute myeloid leukemia","volume":"30","author":"Tsai","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.05.005_bib0031","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.05.005_bib0032","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood-2010-12-327072","article-title":"The FLT3 ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype","volume":"119","author":"Schneider","year":"2012","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:45Z","timestamp":1761871065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2152265021001816"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLT3-ITD Allele Frequency Is an Independent Prognostic Factor for Poor Outcome in FLT3-ITD\u2013Positive AML Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}